Lastly, we further established the C4-2B-Enza-R tumor xenograft models and found that ORC1 knockdown could render C4-2B-Enza-R tumors sensitive to enzalutamide treatment, as quantified by tumor volumes and weight (Figs. 7G–7I). This evidence concerns the gene ORC1 and neoplasm.